Valsacor

Selected form

Valsartan

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Hypotensive

Treatment option: Hypertension, Hypertension In Children, Heart Failure, Heart Attack

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valsacor

Property	Description
Active ingredient	Valsartan
Form	Oral tablet, Oral suspension
Pharmacological class	Angiotensin II Receptor Blocker (ARB)
Common use	Lowering high blood pressure
Origin	Synthetic compound

Valsacor is a prescription-only medication whose active ingredient is Valsartan, categorized as an Angiotensin II Receptor Blocker (ARB). The drug is clinically recognized for its role in cardiovascular management, often being considered for adult patients needing sustained reduction of arterial pressure.

What is the Core Identity of Valsacor?

Valsacor is a brand name for a medicine containing the active ingredient Valsartan, which belongs to the Angiotensin II Receptor Blocker (ARB) pharmacological class. This classification identifies it as a modern, targeted antihypertensive agent designed to regulate the circulatory system. Valsartan is a purely synthetic compound, deliberately engineered to modulate the Renin-Angiotensin-Aldosterone System (RAAS), a hormonal cascade critical to fluid balance and vascular tone.

What is Valsacor's Active Composition and Form?

The active composition of Valsacor centers entirely on Valsartan, making it a single-ingredient product designed for oral use. Its distinct feature is its availability not only as an oral tablet but also in a specific oral suspension (liquid) form. The liquid form is a key factor, allowing for accurate dosage adjustments and simpler administration for patients, such as specific pediatric groups, who may have difficulty swallowing solids. The preparation's nature as an orally administered pharmaceutical emphasizes its convenience for long-term therapeutic application.

What is the General Therapeutic Purpose of Valsartan?

The general purpose of Valsartan is to lower elevated blood pressure and reduce the strain placed on the heart and blood vessels. It achieves this effect by acting as an antagonist that prevents a powerful natural hormone, Angiotensin II, from binding to its receptor sites. This blocking action promotes the relaxation and widening (vasodilation) of arteries and veins, allowing blood to flow more easily. Valsartan is utilized as a medicine primarily for its ability to manage hypertension and mitigate its long-term cardiovascular consequences.

What side effects are possible with Valsacor?

Possible Side Effects and Safety Information

The safety profile of Valsacor (Valsartan) is officially documented and classified by regulatory agencies based on the frequency and physiological system affected. Adverse reactions are grouped using frequency terms such as Common, Uncommon, and Not Known (for post-marketing reports where exact incidence is not estimable).

Documented Adverse Reactions

Adverse reactions are classified into System-Organ Classes (SOCs), with effects noted in the Nervous System (e.g., dizziness, headache) and Vascular System (e.g., hypotension). Reactions classified as Common typically include dizziness, headache, and fatigue. Uncommon reactions may involve cough, vertigo, and abdominal pain.

Category	Examples (SOC)
Common Effects	Dizziness, Headache, Hypotension (Vascular, Nervous System)
Uncommon Effects	Cough, Vertigo, Nausea (Respiratory, Nervous, Gastrointestinal)
Serious Adverse Reactions	Angioedema, Renal failure (Immune, Renal Systems)

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions explicitly documented in regulatory labeling include angioedema (swelling involving the immune system) and the potential for renal impairment or failure. The drug is subject to specific safety constraints for certain patient groups. It is formally contraindicated during the second and third trimesters of pregnancy and in individuals with severe hepatic impairment or biliary obstructive disorders. Hypotension is noted as being more frequently observed in volume-depleted patients or at the initiation of treatment. Furthermore, concomitant use with potassium supplements or potassium-sparing diuretics is documented to increase the risk of Hyperkalemia (elevated potassium levels).

Overdose and Emergency Response

The official regulatory profile for a Valsacor (Valsartan) overdose focuses on the consequences of severe blood pressure reduction. The most likely manifestation of an acute overdose is profound hypotension, which can cause symptoms such as dizziness and fainting. Changes in heart rhythm, including a fast or slow heartbeat, are also documented clinical signs.

Mandated Emergency Actions

In the event that an overdose is suspected, the immediate regulatory guidance is to call the poison control helpline. Certain clinical signs indicate a life-threatening scenario that requires immediate medical assistance. These severe manifestations include collapse, having a seizure, experiencing trouble breathing, or being unable to be awakened. For these conditions, emergency services must be called without delay.

Official Management and Procedural Notes

No specific antidote is known to reverse the effects of a Valsartan overdose. Therefore, treatment is defined as symptomatic and supportive. Clinical management focuses on stabilizing blood pressure and monitoring vital signs. If severe hypotension occurs, blood pressure restoration may be required, often involving the intravenous administration of normal saline. It is a documented procedural fact that the active ingredient, Valsartan, is not removed from the plasma by hemodialysis.

Therapeutic Uses of Valsacor

Valsacor (Valsartan) is commonly used for the management of chronic cardiovascular conditions, offering benefits that provide supportive relief when symptoms interfere with routine activities and contributes to easing the overall symptom load. Its main uses are divided into three key therapeutic areas.

Managing Chronic and Sustained High Blood Pressure

The medication is generally used to help address symptoms related to heightened physiological activity that define hypertension in adults and relevant pediatric patient groups. The primary therapeutic contexts include the long-term management of hypertension, support for heart failure, and its use in clinical scenarios following a heart attack. It is commonly used to help with blood pressure lowering, which may support a reduction in the severity of future cardiovascular event risk, and helps support general well-being during symptomatic phases.

“This medication is applied across domains where additional symptomatic support is needed to address systemic imbalance and support cardiovascular stability.”

Supporting Management and Organ Function

Valsacor is applied in clinical settings that involve symptoms linked to organ-specific functional stress, particularly for kidney support in patients who have Type 2 diabetes alongside hypertension, and is relevant for supporting functional stability of organs. This use supports easing the overall symptom load by being relevant in conditions where symptoms linked to organ-specific functional stress are present.

Quick Fact: Relief for Chronic Conditions
Valsacor is relevant for easing symptoms in conditions characterized by periods of heightened systemic pressure and is applied across domains where additional symptomatic support is needed.

Regulatory References

NIH DailyMed Label for Valsartan

Eligibility and Restrictions for Use

Eligibility and Contraindications for Valsacor

Valsacor (Valsartan) is a prescription-only medicine with specific population-eligibility rules established by government regulatory authorities.

Classification	Population or Condition
Absolutely Contraindicated	Second and third trimesters of pregnancy (due to fetal risk)
	Severe hepatic impairment, biliary cirrhosis, or cholestasis
	Concomitant use with Aliskiren in patients with diabetes mellitus or GFR < 60 mL/min/1.73 m^2
Not Recommended	Children under 1 year of age
	Breastfeeding women
	Pediatric patients (<18 years) for heart failure or post-myocardial infarction

Eligibility is defined by age, organ function, and specific clinical situations. The drug is approved for adults across all its indications (Hypertension, Heart Failure, Post-MI) and for pediatric patients (ages 1 year and older) for Hypertension only. Patients with mild-to-moderate renal or hepatic impairment generally require no initial dose adjustment, but use requires caution in cases of severe renal impairment or mild-to-moderate hepatic impairment without cholestasis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Valsacor (Valsartan) details specific substance combinations that may alter drug exposure or result in heightened pharmacological effects, as documented in official regulatory labeling.

Contraindicated and Restricted Combinations

Co-administration with Aliskiren is contraindicated in patients with Type 2 diabetes or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m²). This restriction is due to the increased risk of hyperkalemia, hypotension, and impaired renal function resulting from Dual RAAS Blockade. The combination of Valsartan with ACE Inhibitors is also generally not recommended for this reason.

Pharmacodynamic and Exposure Interactions

Interacting Substance	Official Interaction Outcome	Mechanism Basis (Label Description)
Potassium-Sparing Diuretics & Supplements	Increased risk of hyperkalemia (elevated serum potassium)	Pharmacodynamic interaction
NSAIDs	Attenuation of antihypertensive effect; increased risk of worsening renal function	Pharmacodynamic interaction
Lithium	Reversible increase in serum lithium concentration and toxicity	Reduced renal clearance
OATP/MRP2 Transporter Inhibitors	Increased systemic exposure (AUC) of Valsartan	Inhibition of hepatic uptake/efflux transporters
Food	Significant reduction in systemic exposure (AUC decreased by ~48%)	Altered absorption

No mandatory timing-based separation requirements are explicitly documented in regulatory labels. The interaction profile highlights that the Aliskiren contraindication is specifically constrained by the patient's existing condition (Type 2 diabetes or renal impairment).

Mechanism of Action

How Valsacor Works

Valsacor (valsartan) is an Angiotensin II Receptor Blocker (ARB), a molecule that modulates the Renin-Angiotensin-Aldosterone System (RAAS). Its primary molecular target is the Angiotensin II type 1 ( AT1) receptor, which is expressed on the surface of various tissues, including vascular smooth muscle, the heart, and the adrenal gland.

Valsartan functions as a selective, competitive antagonist, binding to the AT1 receptor with high affinity. This molecular interaction prevents the key signaling molecule, Angiotensin II, from binding to and activating the receptor. The resultant blockade inhibits the downstream cellular signaling cascades typically initiated by AT1 receptor activation.

Physiologically, blocking the AT1 receptor attenuates several systemic effects: it reduces the direct vasoconstriction of blood vessels and diminishes the Angiotensin II-mediated stimulation of aldosterone release from the adrenal cortex. The system-level physiological consequence is a decrease in peripheral vascular resistance and a reduction in renal sodium and water reabsorption, leading to modulation of circulatory volume.

Dosage and Administration Information

Valsacor is administered solely by the oral route, available as tablets in strengths that typically range from 40 mg to 320 mg. An oral suspension form may be used for patients, such as younger pediatric groups, who are unable to swallow tablets. The tablets and suspension are generally not substitutable on a milligram-for-milligram basis due to differing systemic exposure, requiring dose adjustment when switching forms. The medicine may be taken with or without food.

Official Dosing Schedules

Administration frequency and dosage are strictly determined by the patient's condition and require a titration (gradual dose increase) phase to reach the target maintenance dose, not to exceed 320 mg total daily dose.

Indication (Adult)	Starting Dose	Frequency	Target Max Dose
Hypertension	80 mg or 160 mg	Once daily	320 mg once daily
Heart Failure	40 mg	Twice daily	160 mg twice daily
Post-Myocardial Infarction	20 mg	Twice daily	160 mg twice daily

For heart failure, dose increases are performed at intervals of at least two weeks. For post-myocardial infarction use, therapy may be initiated as early as 12 hours post-event in clinically stable patients, with subsequent titration to the target dose over weeks.

Special Populations: No initial dose adjustment is required for older adults or for patients with mild to moderate renal impairment. For patients with mild to moderate hepatic impairment without cholestasis, the dose should not exceed 80 mg. In the event of a missed dose, the standard procedure is to take it as soon as remembered unless it is near the time for the next scheduled dose, in which case the missed dose is skipped.

Recent Clinical Evidence

Evidence for the Management of Chronic High Blood Pressure

Research exploring Valsacor for essential high blood pressure was primarily structured as Randomized Controlled Trials (RCTs) over both short- and long-term periods. These studies were evaluated for patterns in blood pressure levels and monitored the rates of major cardiovascular events, such as heart attack and stroke, over the study duration. Evidence highlights that the blood pressure response observed may vary across different patient groups, and data for certain high-risk groups remain insufficient.

Evidence for Supporting Heart Function in Heart Failure

Research for Valsacor was evaluated in large-scale, long-term RCTs that included adults with chronic heart failure or those who recently experienced a heart attack. Studies monitored outcomes related to systemic or functional imbalance, specifically looking at all-cause mortality, cardiovascular mortality, and the frequency of hospitalization linked to heart failure. Long-term data on functional measures extending beyond a few years is not fully established, and evidence is limited for patients with heart failure where the heart's pumping function is preserved.

Evidence for Organ Function in Type 2 Diabetes

Research examined temporary physiological imbalance, with some studies exploring outcomes linked to organ function in patients who have Type 2 diabetes and concurrent high blood pressure. Studies monitored changes in albumin excretion in the urine (a marker monitoring physiological strain). Much of this research relies on surrogate markers rather than long-term, definitive clinical outcomes, and data for patients with more advanced chronic kidney disease remain insufficient.

What Remains Unclear in the Research Landscape

Short-term studies (lasting 4 to 12 weeks) track initial changes, while long-term outcome trials follow patients for up to five years or more to monitor major events. The evidence highlights what is known, and also what is still uncertain. Research is ongoing regarding newer scenarios, and certainty remains low for outcomes in certain narrow patient groups. The reliance on surrogate markers in some trials, and a lack of long-term data relative to certain newer therapeutic approaches, are areas where further research is needed.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Valsacor (FAQ)

Q: Is Valsacor typically prescribed for children or just adults?

Valsacor is approved for the treatment of high blood pressure (hypertension) in both adults and pediatric patients who are six years of age and older. Official product information indicates that it is generally not recommended for children under six years old for this specific condition.

Q: How long does it take for Valsacor to start working to lower blood pressure?

Clinical studies and official information suggest that after a single dose, the medicine may begin to show a reduction in blood pressure within about two hours, with the peak effect generally observed within six hours. The full antihypertensive effect is typically reached after about four weeks of repeated, regular use.

Q: What is the recommended dose of Valsacor for a patient with mild to moderate kidney problems?

Regulatory documents state that for adults with mild to moderate kidney impairment (defined by specific laboratory values), an initial dose adjustment is generally not necessary according to official product labeling. Any decision regarding dose and suitability for a patient with kidney conditions must be made by a healthcare professional.

How should Valsacor be stored and disposed of?

Valsartan storage and disposal must strictly follow regulatory guidance to ensure product integrity and safety.

Storage Requirements

Valsartan tablets and solutions must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication should be kept in its original container and protected from light, especially the compounded suspension, which requires an amber glass bottle.

Stability Constraint	Condition
Compounded Suspension (Refrigerated)	Stable for up to 75 days (2 C to 8 C)
Compounded Suspension (Room Temp)	Stable for up to 30 days (below 30 C)

Disposal and Safety

All forms of Valsartan must be stored out of the sight and reach of children.

Disposal of unused or expired medicine should be done through a drug take-back program. If one is unavailable, the medicine must be mixed with an unappealing substance, sealed, and placed in the household trash, avoiding disposal via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.